Cargando…

Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy

BACKGROUND: Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization of exosomes in biofluids have been attempted. We report a protocol to isol...

Descripción completa

Detalles Bibliográficos
Autores principales: Malla, Bijaya, Aebersold, Daniel M., Dal Pra, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090775/
https://www.ncbi.nlm.nih.gov/pubmed/30103771
http://dx.doi.org/10.1186/s12967-018-1592-6
_version_ 1783347256559140864
author Malla, Bijaya
Aebersold, Daniel M.
Dal Pra, Alan
author_facet Malla, Bijaya
Aebersold, Daniel M.
Dal Pra, Alan
author_sort Malla, Bijaya
collection PubMed
description BACKGROUND: Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization of exosomes in biofluids have been attempted. We report a protocol to isolate and characterize exosomal miRNAs content and assess radiation-induced changes. METHODS: In this pilot study, we performed targeted exosomal miRNA profiling of 25 serum samples obtained from PCa patients with intermediate- and high-risk disease treated with curative radiotherapy (RT), and controls. Post-treatment blood samples were collected at least 28 days after radiation therapy as a paired follow-up sample. The complete workflow consisted of two phases: I) filtration and polyethylene glycol salt precipitation phase which enriched particles below 200 nm in size followed by characterization using electron microscopy, and II) flow cytometry. Finally, miRNA expression analysis between untreated and treated patient samples was performed using RNA extraction kit, and qRT-PCR. RESULTS: In our preliminary data, 1 ml of serum from PCa patients showed higher exosomal concentration (3.68E+10) compared to controls (6.07E+08). The overall expression of exosomes after RT was found to be higher compared to untreated samples; the median value changed from 3.68E+10 to 5.40E+10; p = 0.52. Using electron microscopy, we were able to visualize cup-shaped vesicles with morphology and size compatible with exosomes. The bead-based flow cytometry showed positivity for exosomal tetraspanins surface markers CD63 and CD9. All five miRNAs (hsa-let-7a-5p, hsa-miR-141-3p, hsa-miR-145-5p, hsa-miR-21-5p, hsa-miR-99b-5p) have been identified in exosomes. Despite overall changes in hsa-let-7a-5p expression after radiation, the difference was significant only in the high-risk group (p = 0.037). In addition, the radiation response to hsa-miR-21-5p was elevated in the high-risk group compared to the intermediate group (p = 0.036). CONCLUSIONS: Herewith, we demonstrated a protocol for isolation of serum exosomes and exosomal miRNA amplification. The recovery of exosomal miRNAs and their differential expression after radiation treatment suggests promising biomarker potential that requires further investigation in larger patient cohorts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1592-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6090775
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60907752018-08-17 Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy Malla, Bijaya Aebersold, Daniel M. Dal Pra, Alan J Transl Med Research BACKGROUND: Circulating exosomes from prostate cancer (PCa) patients undergoing radiotherapy are attractive candidate biomarkers for monitoring treatment response. Multiple workflows for isolation and content characterization of exosomes in biofluids have been attempted. We report a protocol to isolate and characterize exosomal miRNAs content and assess radiation-induced changes. METHODS: In this pilot study, we performed targeted exosomal miRNA profiling of 25 serum samples obtained from PCa patients with intermediate- and high-risk disease treated with curative radiotherapy (RT), and controls. Post-treatment blood samples were collected at least 28 days after radiation therapy as a paired follow-up sample. The complete workflow consisted of two phases: I) filtration and polyethylene glycol salt precipitation phase which enriched particles below 200 nm in size followed by characterization using electron microscopy, and II) flow cytometry. Finally, miRNA expression analysis between untreated and treated patient samples was performed using RNA extraction kit, and qRT-PCR. RESULTS: In our preliminary data, 1 ml of serum from PCa patients showed higher exosomal concentration (3.68E+10) compared to controls (6.07E+08). The overall expression of exosomes after RT was found to be higher compared to untreated samples; the median value changed from 3.68E+10 to 5.40E+10; p = 0.52. Using electron microscopy, we were able to visualize cup-shaped vesicles with morphology and size compatible with exosomes. The bead-based flow cytometry showed positivity for exosomal tetraspanins surface markers CD63 and CD9. All five miRNAs (hsa-let-7a-5p, hsa-miR-141-3p, hsa-miR-145-5p, hsa-miR-21-5p, hsa-miR-99b-5p) have been identified in exosomes. Despite overall changes in hsa-let-7a-5p expression after radiation, the difference was significant only in the high-risk group (p = 0.037). In addition, the radiation response to hsa-miR-21-5p was elevated in the high-risk group compared to the intermediate group (p = 0.036). CONCLUSIONS: Herewith, we demonstrated a protocol for isolation of serum exosomes and exosomal miRNA amplification. The recovery of exosomal miRNAs and their differential expression after radiation treatment suggests promising biomarker potential that requires further investigation in larger patient cohorts. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1592-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-08-13 /pmc/articles/PMC6090775/ /pubmed/30103771 http://dx.doi.org/10.1186/s12967-018-1592-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Malla, Bijaya
Aebersold, Daniel M.
Dal Pra, Alan
Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
title Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
title_full Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
title_fullStr Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
title_full_unstemmed Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
title_short Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy
title_sort protocol for serum exosomal mirnas analysis in prostate cancer patients treated with radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090775/
https://www.ncbi.nlm.nih.gov/pubmed/30103771
http://dx.doi.org/10.1186/s12967-018-1592-6
work_keys_str_mv AT mallabijaya protocolforserumexosomalmirnasanalysisinprostatecancerpatientstreatedwithradiotherapy
AT aebersolddanielm protocolforserumexosomalmirnasanalysisinprostatecancerpatientstreatedwithradiotherapy
AT dalpraalan protocolforserumexosomalmirnasanalysisinprostatecancerpatientstreatedwithradiotherapy